SAN DIEGO, CA--(Marketwire - Jan 8, 2013) - Medistem Inc. (
"To my knowledge Medistem is the only company in the history of cell therapy to take a cell from discovery to FDA clearance and clinical trials in the span of 4 years," said Dr. Chiplin. "I believe Medistem has an outstanding management team and have watched with great interest the company's evolution. I believe the company is well positioned to transform the stem cell industry and I look forward to helping shape the company's future as a member of the board."
Dr. Chiplin has broad-based experience in the life science and technology industries in both leadership and investment roles. Prior to Polynoma, Dr. Chiplin was founding CEO of Arana Therapeutics, a new generation antibody developer and a board member of Domantis, Inc., prior to the acquisition of these companies by Cephalon ($329 million) and GSK ($458 million), respectively. Prior to founding Arana, Dr. Chiplin was Managing Director of U.K. based ITI Life Sciences investment Fund. Dr. Chiplin holds Pharmacy and Doctoral degrees from the University of Nottingham, UK.
"We are delighted to have John join our board. The combination of scientific and business acumen, as well as practical knowledge of biotherapeutic development that John possesses is an extremely rare combination," said Alan Lewis, Ph.D., CEO of Medistem. "John has been involved in several successful exits, we are looking forward to synergizing with his talents at optimizing the value of our universal donor stem cell product."
About Medistem Inc.
Medistem Inc., is focused on the development of the Endometrial Regenerative Cell (ERC), a universal donor adult stem cell product. ERCs possess specialized abilities to stimulate new blood vessel growth and can differentiate into lung, liver, heart, brain, bone, cartilage, fat and pancreatic tissue. These unique properties have applications for treatment of critical limb ischemia (CLI), congestive heart failure (CHF), neurodegenerative diseases, liver failure, kidney failure, and diabetes. ERCs have been cleared by the FDA to begin studies in the United States.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Medistem Inc. These can be identified by the use of forward‐looking words, such as "believes," "expects," "may," "intends," "anticipates," "plans," "estimates," or any other analogous or similar expressions intended to identify forward‐looking statements. These forward‐looking statements and estimates as to future performance, estimates, and other statements contained herein regarding matters that are not historical facts, are only predictions and actual events or results may differ materially. We cannot assure or guarantee that any future results described in this presentation will be achieved, and actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.